©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Surg. Dec 27, 2015; 7(12): 356-359
Published online Dec 27, 2015. doi: 10.4240/wjgs.v7.i12.356
Published online Dec 27, 2015. doi: 10.4240/wjgs.v7.i12.356
New active drugs for the treatment of advanced colorectal cancer
Alberto Zaniboni, Medical Oncology Unit, Fondazione Poliambulanza, 25124 Brescia, Italy
Author contributions: Zaniboni A solely contributed to this paper.
Conflict-of-interest statement: None.
Correspondence to: Alberto Zaniboni, MD, Medical Oncology Unit, Fondazione Poliambulanza, Via Bissolati 57, 25124 Brescia, Italy. alberto.zaniboni@poliambulanza.it
Telephone: +39-30-3515553 Fax: +39-30-3515942
Received: May 23, 2015
Peer-review started: May 25, 2015
First decision: August 16, 2015
Revised: September 27, 2015
Accepted: October 16, 2015
Article in press: October 19, 2015
Published online: December 27, 2015
Processing time: 215 Days and 8.5 Hours
Peer-review started: May 25, 2015
First decision: August 16, 2015
Revised: September 27, 2015
Accepted: October 16, 2015
Article in press: October 19, 2015
Published online: December 27, 2015
Processing time: 215 Days and 8.5 Hours
Core Tip
Core tip: A brief review dealing with four new active drugs for the treatment of metastatic colorectal cancer covering also the very recent publication of the Tas-102 trial on New England Journal of Medicine.